PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced its participation in the 2023 American Academy of Neurology Annual Meeting from April 22-27 in Boston. The company will feature two oral and two poster presentations, highlighting advancements in treatments for Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Ashling Holland, Ph.D., will present preclinical data for DM1 on April 27, while two presentations on DMD will occur on April 23, showcasing results from a Phase 1 study of PGN-EDO51 and a study design for PGN-EDODM1. PepGen aims to revolutionize the treatment landscape for severe neuromuscular diseases through its Enhanced Delivery Oligonucleotide platform, demonstrating a commitment to addressing these critical health challenges.
- None.
- None.
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts.
Oral Presentation:
Title: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Program Number: S48.001
Session Topic: Therapeutics for Muscle Disease
Date & Time: Thursday, April 27, 2023 at 3:30pm ET
Presenter: Ashling Holland, Ph.D., Director of Preclinical Development
Poster Presentation:
Title: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD)
Program Number: P3.002
Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 1
Date & Time: Sunday, April 23, at 5:30pm ET
Presenter: Ashling Holland, Ph.D., Director of Preclinical Development
Title: PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD): Results of a Phase 1 Study in Healthy Volunteers
Program Number: P3.004
Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 1
Date & Time: Sunday, April 23, at 5:30pm ET
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
Title: Design of a Phase 1, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (DM1)
Program Number: P6.004
Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 3
Date & Time: Monday, April 24, at 5:30pm ET
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the potential therapeutic benefits and safety profile of our candidates, initiation of the Phase 2 studies in PGN-EDO51 and the Phase 1 study in PGN-EDODM1, our interpretation of clinical and preclinical study results and how they may impact our programs, the filing of an IND application for PGN-EDODM1, scheduled participation and presentation of information in conferences and statements about our clinical and preclinical programs, product candidates, expected cash runway, achievement of milestones, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully initiate or complete our planned clinical trials for PGN-EDO51 and and PGN-EDODM1 and preclinical studies of other product candidates or to obtain regulatory approval before commercialization for marketing of such products; our interpretation of clinical and preclinical study results may be incorrect; our product candidates may not be safe and effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; we may not be able to nominate new drug candidates within the estimated timeframes; our estimation of addressable markets of our product candidates may be inaccurate; we may need additional funding before the end of our expected cash runway and may fail to timely raise such additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to take advantage of certain accelerated regulatory pathways; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; we may encounter liquidity distress due to failure of financial institutions with which we maintain relationship; and we are dependent on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent annual report on Form 10-K to be filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com
Media Contact
Sarah Sutton
Argot Partners
pepgen@argotpartners.com
FAQ
What presentations will PepGen Inc. make at the 2023 AAN Annual Meeting?
When is PepGen's oral presentation scheduled during the AAN meeting?
What is the focus of PepGen's research presented at the AAN 2023?
Who will present PepGen's research at the AAN Annual Meeting?
What is the significance of the research presented by PepGen at the AAN meeting?
